Details for Patent: 8,318,682
✉ Email this page to a colleague
Which drugs does patent 8,318,682 protect, and when does it expire?
Patent 8,318,682 protects VEKLURY and is included in one NDA.
Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty-six patent family members in thirty-two countries.
Summary for Patent: 8,318,682
| Title: | 1'substituted carba-nucleoside analogs for antiviral treatment |
| Abstract: | Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1' position of the nucleoside sugar is substituted with a cyano group. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. |
| Inventor(s): | Butler; Thomas (Redwood City, CA), Cho; Aesop (Mountain View, CA), Kim; Choung U. (San Carlos, CA), Parrish; Jay P. (Redwood City, CA), Saunders; Oliver L. (San Mateo, CA), Zhang; Lijun (Los Altos Hills, CA) |
| Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
| Application Number: | 13/196,117 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,318,682
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,318,682
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2937350 | ⤷ Sign Up | LUC00193 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2937350 | ⤷ Sign Up | PA2020539 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2937350 | ⤷ Sign Up | CA 2020 00060 | Denmark | ⤷ Sign Up |
| European Patent Office | 2937350 | ⤷ Sign Up | CR 2020 00060 | Denmark | ⤷ Sign Up |
| European Patent Office | 2937350 | ⤷ Sign Up | PA2020539,C2937350 | Lithuania | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
